ENDO12 |
Catalog No.GC79440
One-Click Copy Product Info
|
ENDO12 is an inhibitor of the Munc13-4-STX7 protein complex, with a K d value of 2.7 µM for STX7.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, ENDO12 (30 mg/kg; i.p.; single dose; 1 hour before CpG challenge) reduces CpG-induced systemic inflammation in mice, lowering plasma IL-6, IFNγ, and MPO levels[1]. ENDO12 (15 mg/kg; i.p.; single dose; 1 hour before LCMV infection) does not impair the host antiviral response to LCMV infection in mice, with only minimal reduction in MIP1β and MIP2 levels[1].
In Vitro, ENDO12 (31.25 nM-3 μM) binds to recombinant STX7 with a Kd value of 2.7 µM, showing higher affinity than ENDO3[1]. ENDO12 potently inhibits CpG-induced TLR9 activation in HEK-Blue hTLR9 cells, with an IC50 of 1 × 10-7 M[1]. ENDO12 (10 µM; 1 h) reduces the colocalization levels of STX7 with Munc13-4, TLR7 with LAMP1, and TLR9 with LAMP1 in RAW 264.7 mouse macrophages, thereby inhibiting endosome maturation and TLR trafficking[1].
References:
[1]. Johnson JL, et al. Munc13-4-STX7 inhibitors impair endosomal TLR activation and systemic inflammation. Nat Chem Biol. Published online April 6, 2026.
| Cas No. | SDF | ||
| Formula | C15H17FN4O | M.Wt | 288.32 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4684 mL | 17.3418 mL | 34.6837 mL |
| 5 mM | 693.7 μL | 3.4684 mL | 6.9367 mL |
| 10 mM | 346.8 μL | 1.7342 mL | 3.4684 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)